Major Events - Heng Rui Medicine (01276) has received the clinical trial approval notice for Adalimumab injection [1] - Anjoy Foods (02648) plans to increase capital by 120 million yuan to its subsidiary in Henan [1] - Xuan Zhu Bio-B (02575) has been included in the Hong Kong Stock Connect stock list [1] - Peijie Biopharma-B (02565) reports one-month clinical observation results from the first human trial of its next-generation GLP-1 (CR059) [1] - Changfeng Pharmaceutical (02652) has been included in the Hong Kong Stock Connect eligible securities list [1] - Binhai Investment (02886) has secured financing of up to 45 million USD and 173 million yuan in various currency term loans [1] - He Yu-B (02256) reports results from the global Phase III MANEUVER study of Beijiemai® published in The Lancet [1] Operating Performance - Yuexiu Property (00123) reported a cumulative contract sales amount of approximately 7.106 billion yuan in the first two months [1] - Mengniu Dairy (02319) expects annual profit attributable to shareholders to be approximately 1.4 billion to 1.6 billion yuan [1] - Dongfeng Motor Group (00489) reported cumulative automobile sales of 228,518 units in the first two months, a year-on-year increase of approximately 1.2% [1] - Shangmei Co. (02145) issued a profit warning, expecting a profit of approximately 1.14 billion to 1.16 billion yuan for 2025, a year-on-year increase of approximately 41.9% to 44.4% [1] - Longfor Group (00960) achieved a total contract sales amount of 4.45 billion yuan in the first two months [1] - ZTE Corporation (00763) reported a net profit attributable to shareholders of 5.618 billion yuan for 2025, a year-on-year decrease of 33.32% [1] - Huishang Bank (03698) issued a positive profit forecast, expecting a net profit of approximately 16.93 billion yuan for 2025, a year-on-year increase of approximately 6.3% [1] - Sun Hung Kai Properties (00086) issued a profit warning, expecting a consolidated profit attributable to shareholders of no less than 1.5 billion HKD for 2025 [1]

Group 1 - In 2025, there were 116 new companies listed on A-shares and 119 on Hong Kong stocks, with sectors including AI chips, semiconductor materials, new energy vehicles, chain consumption, and innovative pharmaceuticals [2][3] - The article highlights the increasing presence of female founders and co-founders in these newly listed companies [3] Group 2 - Moore Threads, co-founded by Zhou Yuan, is a notable GPU startup that went public in December 2025 with an initial market value exceeding 300 billion RMB [5][7] - MiniMax, co-founded by Yuan Yeyi, became the fastest AI model company to complete an IPO in January 2026, with a market value of 2230.11 billion RMB [9][10] - Light Health Group, led by Yang Yin, transitioned from a crowdfunding platform to a digital health service provider, achieving a market value of 157.85 billion RMB after its IPO [15][18] - Aixin Yuan Zhi, founded by Qiu Xiaoxin, became the first Chinese edge AI chip company to go public, with a market value of 146.31 billion RMB [20][23] - Baiao Saitou, co-founded by Ni Jian, went public on the STAR Market with a market value of 346.35 billion RMB, focusing on biopharmaceuticals [25][26] - Muxi Co., Ltd., co-founded by Peng Li, is another GPU company that went public in December 2025, with a market value of 2135.41 billion RMB [30][32] - Baoji Pharmaceutical, co-founded by Wang Zheng, achieved a market value of 291.44 billion RMB after its IPO, focusing on gene-engineered drugs [36][38] - Yunji Technology, founded by Zhi Tao, became the first company in the robot service sector to go public, with a market value of 92.79 billion RMB [42][43] - Haibo Shichuang, with Xu Rui as the only female executive, is a leading provider of electrochemical energy storage solutions, listed on the STAR Market [45][46] - Xuan Zhu Biotech, led by Xu Yanjun, focuses on innovative drug development and went public with a market value of 228.60 billion RMB [48][51] Group 3 - The article emphasizes that the presence of women in entrepreneurial and management roles is growing, with many women becoming founders, partners, and core managers in various companies [53] - The narrative celebrates women's contributions to entrepreneurship, suggesting that their impact extends beyond traditional roles [54]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） 自願公告 本公司股份納入港股通股票名單 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」或「軒竹生物」，連 同 其 附 屬 公 司，統 稱 為 「本集團」）董 事 會（「董事會」）欣 然 宣 佈，根 據 上 海 證 券 交 易 所 及 深 圳 證 券 交 易 所 於2026年3月6日 分 別 發 佈 的《關 於 滬 港 通 下 港 股 通 標 的 調 整 的 通 知》、《關 於 深 港 通 下 的 港 股 通 標 的 證 券 名 單 調 整 的 公 告》，本 公 司 被 調 入 滬 港 通 與 深 港 通 下 港 股 通 標 的 名 單，自2026年3月9日 起 正 式 生 效。 滬港通及深港通 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 軒竹生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02575 | 說明 | H股 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 160,701,996 | RMB | | | 1 RMB | | 160,701,996 | | 增加 / 減少 (-) | | | | | | | RMB | | | | 本月底結存 | | | 160,701,996 | RMB | | | 1 RMB | | 1 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） （股份代號：2575） 自願公告 軒悅寧® （吡 洛 西 利 片）第 三 個 適 應 症 上 市 申 請 獲 得NMPA批 准， 用於一線治療HR+╱HER2-晚期乳腺癌 本次新適應症的獲批主要基於BRIGHT-3研究(NCT05257395)的數據結果。BRIGHT-3 研究是一項在中國58家 中 心 開 展 的 隨 機、雙 盲 的III期 臨 床 試 驗，旨 在 評 估 吡 洛 西利聯合來曲唑或阿那曲唑一線治療HR+╱HER2-晚期乳腺癌的有效性和安全 性。此 前，BRIGHT-3的研究成果在2025年 歐 洲 腫 瘤 內 科 學 會（「2025年ESMO」）首 次 發 表。結 果 顯 示，在 療 效 ...

Core Viewpoint - The company, Xuan Zhu Bio-B (02575.HK), has been included in the Hang Seng Composite Index, effective March 9, 2026, reflecting investor recognition of its value and growth potential [1] Group 1: Inclusion in Hang Seng Composite Index - The inclusion in the Hang Seng Composite Index is based on the quarterly review results announced by Hang Seng Indexes Company on February 13, 2026, for the period ending December 31, 2025 [1] - The Hang Seng Composite Index covers the top 95% of listed companies on the Hong Kong Stock Exchange by cumulative market capitalization [1] - Being part of the index is expected to meet the inclusion criteria for the Stock Connect programs, facilitating trading between Hong Kong and mainland Chinese investors [1] Group 2: Implications of Inclusion - The board believes that inclusion in the index will enhance the company's stock liquidity, broaden the investor base, and enrich the shareholder structure [1] - This development is anticipated to further elevate the company's reputation and investment value in the capital market, contributing to its long-term stable growth [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 全部或任何部份內容而產生或因倚賴該等內容而引致之任何損失承擔任何責 任。 Xuanzhu Biopharmaceutical Co., Ltd. 軒竹生物科技股份有限公司 （一家於中華人民共和國註冊成立的股份有限公司） 本公司獲納入恒生綜合指數成份股 本 公 告 乃 由 軒 竹 生 物 科 技 股 份 有 限 公 司（「本公司」，連 同 其 附 屬 公 司「本集團」） 自 願 作 出，以 知 會 股 東 及 潛 在 投 資 者 有 關 本 集 團 之 最 新 業 務 發 展。 本 公 司 董 事 會（「董事會」）欣 然 宣 佈，根 據 恒 生 指 數 有 限 公 司 於2026年2月13日 公 佈的截至2025年12月31日 止 期 間 之 恒 生 指 數 系 列 季 度 檢 討 結 果，本 公 司 被 納 入 恒 生 綜 合 指 數 之 成 分 股，該 調 整 將 於2026年3月9日 正 式 生 效。 恒 生 綜 合 ...

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xuan Bamboo Biotech-B (02575) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Xuan Bamboo Biotech is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - On December 7, 2025, the National Healthcare Security Administration announced the results of the adjustment to the National Medical Insurance Drug List, with Xuan Bamboo Biotech's self-developed Class 1 innovative drug, palbociclib tablets, successfully included in the list [1] - This inclusion provides new benefits for reimbursement to patients with advanced breast cancer [1]

Group 1 - The Hang Seng Index Company announced the quarterly review results for the Hang Seng Index series as of December 31, 2025, with Xuan Bamboo Biotechnology-B (02575) being included in the Hang Seng Composite Index [1] - The changes will be implemented after the market closes on March 6, 2026, and will take effect on March 9, 2026, leading to adjustments in the eligible stocks for the Hong Kong Stock Connect [1] - According to a report by CICC, Xuan Bamboo Biotechnology is likely to be included in the Hong Kong Stock Connect due to meeting various criteria, including market capitalization, liquidity, and listing time [1] Group 2 - On December 7, 2025, the National Healthcare Security Administration announced the results of the adjustment to the National Medical Insurance Drug List, with Xuan Bamboo Biotechnology's self-developed innovative drug, CDK4/6 inhibitor Pyrotinib tablets, successfully included in the list [1] - This inclusion provides new benefits for reimbursement to patients with advanced breast cancer [1]

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年1月31日 狀態: 新提交 致：香港交易及結算所有限公司 備註： 第 1 頁 共 11 頁 v 1.2.0 公司名稱: 軒竹生物科技股份有限公司（於中華人民共和國註冊成立的股份有限公司, 「本公司」） 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02575 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 160,701,996 | RMB | | 1 RMB | | 160,701,996 | | 增加 / 減少 (-) | | | | | | RMB | | | | 本月底結存 | | | 160,701,996 | RMB | | 1 RM ...